Physician profile
Marvin P Baker
NPI 1285661371
$4,846.46
in general payments reported to CMS, 2019-2025
40 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,224 · 2020: $490 · 2021: $800 · 2022: $389 · 2023: $379 · 2024: $295 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.02 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $639.22 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $526.28 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $506.07 | 2019-2022 | |
| Amgen INC. | $445.74 | 2019-2024 | Repatha |
| Pfizer INC. | $260.76 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $255.77 | 2019-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $230.07 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.25 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $159.98 | 2019-2023 | |
| Boston Scientific Corporation | $148.10 | 2019-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $136.19 | 2019-2023 | Camzyos |
| Heartflow, INC. | $116.39 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.20 | 2019-2021 | |
| Amarin Pharma, INC. | $94.22 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.42 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.